An overview of the epidemiology of avian influenza.

Abstract:

:Only viruses of the Influenzavirus A genus have been isolated from birds and termed avian influenza [AI] viruses, but viruses with all 16 haemagglutinin [H1-H16] and all 9 neuraminidase [N1-N9] influenza A subtypes in the majority of possible combinations have been isolated from avian species. Influenza A viruses infecting poultry can be divided into two groups. The very virulent viruses causing highly pathogenic avian influenza [HPAI], with flock mortality as high as 100%. These viruses have been restricted to subtypes H5 and H7, although not all H5 and H7 viruses cause HPAI. All other viruses cause a milder, primarily respiratory, disease [LPAI], unless exacerbated. Until recently HPAI viruses were rarely isolated from wild birds, but for LPAI viruses extremely high isolation rates have been recorded in surveillance studies, with overall figures of about 11% for ducks and geese and around 2% for all other species. Influenza viruses may infect all types of domestic or captive birds in all areas of the world, the frequency with which primary infections occur in any type of bird usually depending on the degree of contact there is with feral birds. Secondary spread is usually associated with human involvement, either by bird or bird product movement or by transferring infective faeces from infected to susceptible birds, but potentially wild birds could be involved. In recent years there have been costly outbreaks of HPAI in poultry in Italy, The Netherlands and Canada and in each millions of birds were slaughtered to bring the outbreaks under control. Since the 1990s AI infections due to two subtypes have been widespread in poultry across a large area of the World. LPAI H9N2 appears to have spread across the whole of Asia in that time and has become endemic in poultry in many of the affected countries. However, these outbreaks have tended to have been overshadowed by the H5N1 HPAI virus, initially isolated in China, that has now spread in poultry and/or wild birds throughout Asia and into Europe and Africa, resulting in the death or culling of hundreds of millions of poultry and posing a significant zoonosis threat.

journal_name

Vaccine

journal_title

Vaccine

authors

Alexander DJ

doi

10.1016/j.vaccine.2006.10.051

subject

Has Abstract

pub_date

2007-07-26 00:00:00

pages

5637-44

issue

30

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(06)01187-X

journal_volume

25

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

    abstract::In this review, published peer-reviewed preclinical studies using prime-boost tuberculosis (TB) vaccine regimens in animal challenge models for tuberculosis have been evaluated. These studies have been divided into groups that describe prime-boost vaccine combinations that performed better than, equivalent to, or wors...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2012.02.036

    authors: Brennan MJ,Clagett B,Fitzgerald H,Chen V,Williams A,Izzo AA,Barker LF

    更新日期:2012-04-16 00:00:00

  • The biology of influenza viruses.

    abstract::The influenza viruses are characterized by segmented, negative-strand RNA genomes requiring an RNA-dependent RNA polymerase of viral origin for replication. The particular structure ofthe influenza virus genome and function of its viral proteins enable antigenic drift and antigenic shift. These processes result in vir...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2008.07.039

    authors: Bouvier NM,Palese P

    更新日期:2008-09-12 00:00:00

  • Inactivated influenza vaccine does not reduce all cause respiratory illness in children with pre-existing medical conditions.

    abstract:BACKGROUND:The effectiveness of inactivated influenza vaccine (IIV) immunization in preventing all cause respiratory illness (RI) in children with pre-existing medical conditions has not been fully established and varies from season to season. This study aims to quantify the overall impact of IIV immunization on primar...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.11.086

    authors: de Hoog MLA,Venekamp RP,Meijer A,Sanders EAM,Bruijning-Verhagen PCJL

    更新日期:2020-04-09 00:00:00

  • Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.

    abstract::H5N1, highly pathogenic avian influenza poses, a threat to animal and human health. Rapid changes in H5N1 viruses require periodic reformulation of the conventional strain-matched vaccines, thus emphasizing the need for a broadly protective influenza vaccine. Here, we constructed BV-Dual-3M2e-LTB, a recombinant baculo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.12.039

    authors: Zhang J,Fan HY,Zhang Z,Zhang J,Zhang J,Huang JN,Ye Y,Liao M

    更新日期:2016-01-27 00:00:00

  • Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.

    abstract::A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-bindi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.02.049

    authors: Khurana S,King LR,Manischewitz J,Coyle EM,Golding H

    更新日期:2014-04-17 00:00:00

  • Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

    abstract:BACKGROUND:Alternative methods for influenza vaccine production are needed to ensure adequate supplies. METHODS:Healthy adults 50-64 years were assigned randomly to receive one intramuscular injection of trivalent recombinant hemagglutinin (rHA) or U.S. licensed trivalent inactivated vaccine (TIV) containing H1, H3 an...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2011.01.039

    authors: Baxter R,Patriarca PA,Ensor K,Izikson R,Goldenthal KL,Cox MM

    更新日期:2011-03-09 00:00:00

  • A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.

    abstract::Forty-four adult patients with cutaneous leishmaniasis (CL) were enrolled in a randomized, double-blind, controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 ant...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2010.07.063

    authors: Nascimento E,Fernandes DF,Vieira EP,Campos-Neto A,Ashman JA,Alves FP,Coler RN,Bogatzki LY,Kahn SJ,Beckmann AM,Pine SO,Cowgill KD,Reed SG,Piazza FM

    更新日期:2010-09-14 00:00:00

  • Studies on the usefulness of intranasal inactivated influenza vaccines.

    abstract::Intranasal inactivated influenza vaccines have the advantage over parenteral vaccines in that they are not associated with the pain of an injection. However, they would be most useful if they were available for all age groups, including high-risk groups, and also would provide cross-protection against variant virus st...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2010.05.019

    authors: Tamura S

    更新日期:2010-08-31 00:00:00

  • Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins.

    abstract::We have evaluated in C57/Bl6 and HLA-A2.1 transgenic mice the immunogenicity of three MVA vectors expressing either native HCV E1E2 polyprotein, truncated and secreted E1 (E'1(311)) and E2 (E'2(661)) proteins, or a chimeric E1E2 heterodimer presented at the plasma membrane. Immunization induced mainly a Th1 response i...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.04.005

    authors: Abraham JD,Himoudi N,Kien F,Berland JL,Codran A,Bartosch B,Baumert T,Paranhos-Baccala G,Schuster C,Inchauspé G,Kieny MP

    更新日期:2004-09-28 00:00:00

  • Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines.

    abstract::Aluminum based adjuvants (alum), including aluminum hydroxide (Alhydrogel) and aluminum phosphate are the most commonly used adjuvant in the US. In order to ensure quality of vaccines, regulatory authorities require evaluation of antigen content in final vaccine products. Currently, there are no generic methods availa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.07.067

    authors: Zhu D,Saul A,Huang S,Martin LB,Miller LH,Rausch KM

    更新日期:2009-10-09 00:00:00

  • Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

    abstract::Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2013.05.013

    authors: Garcia-Angulo VA,Kalita A,Torres AG

    更新日期:2013-07-11 00:00:00

  • Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.

    abstract:BACKGROUND:Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2013.08.064

    authors: Treanor JJ,Essink B,Hull S,Reed S,Izikson R,Patriarca P,Goldenthal KL,Kohberger R,Dunkle LM

    更新日期:2013-11-19 00:00:00

  • Influenza vaccination coverage one year after the A(H1N1) influenza pandemic, France, 2010-2011.

    abstract::We report influenza vaccination coverage in target groups for the 2010-2011 influenza season, one year after the A(H1N1) pandemic. Data were collected through a one-stage cross-sectional national random telephone survey conducted in January 2011 among a sample of the population of mainland France connected to a land t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.011

    authors: Guthmann JP,Fonteneau L,Bonmarin I,Lévy-Bruhl D

    更新日期:2012-02-01 00:00:00

  • Expression of Cathepsin S in BCG converts it into a pro-apoptotic and highly immunogenic strain.

    abstract:BACKGROUND:BCG vaccine, introduced almost 100years ago, is the only option to prevent TB disease. It effectively protects newborns from meningeal TB but fails to prevent adult pulmonary TB. TB kills 1.3million people annually in areas where BCG vaccination is widely practiced. Thus, more effective TB vaccines are urgen...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.02.065

    authors: Lau A,Singh V,Soualhine H,Hmama Z

    更新日期:2017-04-11 00:00:00

  • Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

    abstract::Although a highly effective vaccine against smallpox, vaccinia virus (VV) is not without adverse events, some of which can be life-threatening, particularly in immunocompromised individuals. We have recently demonstrated that the immunogenicity and protective efficacy of Dryvax(®) in immunocompetent mice is preserved ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.10.039

    authors: Berhanu A,King DS,Mosier S,Jordan R,Jones KF,Hruby DE,Grosenbach DW

    更新日期:2010-12-16 00:00:00

  • Protection against influenza virus infection by nasal vaccination in advance of sublethal irradiation.

    abstract::The effect of sublethal gamma-ray irradiation on the protection conferred by a nasal influenza vaccine was investigated in BALB/c mice. A radiation dose of 7 Gy was selected as the sublethal dose as this caused exacerbation of the influenza but was not lethal in the mouse model. Mice were irradiated 7 days before, on ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00553-8

    authors: Hasegawa H,Kadowaki S,Takahashi H,Iwasaki T,Tamura S,Kurata T

    更新日期:2000-05-22 00:00:00

  • Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.

    abstract:BACKGROUND:Human immunodeficiency virus (HIV)-infected persons are at risk for severe influenza infections. Although vaccination against the H1N1 pandemic influenza strain is recommended, currently there are no data on the durability of post-vaccination antibody responses in this population. METHODS:HIV-infected and H...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.02.040

    authors: Crum-Cianflone NF,Iverson E,Defang G,Blair PJ,Eberly LE,Maguire J,Ganesan A,Faix D,Duplessis C,Lalani T,Whitman T,Brandt C,Macalino G,Millar EV,Burgess T

    更新日期:2011-04-12 00:00:00

  • Towards the rational design of Th1 adjuvants.

    abstract::Finding adjuvants in order to enhance immune responses against target immunogens has been a major and recurrent issue for the vaccine industry. It is yet to be solved, most particularly in the context of a growing interest in designing new types of vaccines capable of eliciting Th1 immune responses. A review of synthe...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(01)00193-1

    authors: Moingeon P,Haensler J,Lindberg A

    更新日期:2001-08-14 00:00:00

  • Factors associated with uptake of vaccination against pandemic influenza: a systematic review.

    abstract:BACKGROUND:In June 2009 a global influenza pandemic was declared by the World Health Organisation. A vaccination programme against H1N1 influenza was introduced in many countries from September 2009, but there was low uptake in both the general population and health professionals in many, though not all, countries. PU...

    journal_title:Vaccine

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.vaccine.2011.06.107

    authors: Bish A,Yardley L,Nicoll A,Michie S

    更新日期:2011-09-02 00:00:00

  • Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.

    abstract::Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms in numerous animal and human clinical studies. The immune response induced by Ad5 vaccines can be mitigated due to pre-existing Ad5 immunity. We previously reported the use of a novel Ad5 platform to induce cellular immune responses (C...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.028

    authors: Gabitzsch ES,Xu Y,Yoshida LH,Balint J,Amalfitano A,Jones FR

    更新日期:2009-10-30 00:00:00

  • Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.

    abstract:BACKGROUND:Shigellae cause severe disease in endemic countries, especially in children. Several efficacy trials have been conducted with candidate vaccines against Shigellae, but the lack of protection, the safety concerns, or manufacturing challenges hindered successful market approval. Conjugated vaccines have been s...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2015.06.102

    authors: Hatz CF,Bally B,Rohrer S,Steffen R,Kramme S,Siegrist CA,Wacker M,Alaimo C,Fonck VG

    更新日期:2015-08-26 00:00:00

  • Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster.

    abstract::Data from two Swedish pertussis vaccine trials with various combination vaccines were used to compare anti-diphtheria antitoxin concentrations over time between different vaccines, vaccine lots and vaccine schedules. The immune responses were measured with a validated ELISA method.Results are given for 1326 children, ...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(99)00539-3

    authors: Tiru M,Hallander HO,Gustafsson L,Storsaeter J,Olin P

    更新日期:2000-04-28 00:00:00

  • Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides.

    abstract::CpG oligodeoxynucleotides (ODN) are synthetic DNA sequences that mimic bacterial DNA, and bind to the TLR9 receptor. The cells that express TLR9, B cells and dendritic cells, are stimulated by CpG ODN and induce innate and acquired immune responses. Because CpG ODN induce antigen-independent immune activation there ha...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.11.055

    authors: Wang Y,Krieg AM

    更新日期:2004-06-30 00:00:00

  • Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.

    abstract::Long-term protection of rabbits that had been vaccinated with two doses of a recombinant protective antigen (rPA) vaccine was examined against an aerosol spore challenge with the Ames isolate of Bacillus anthracis at 6 and 12 months. At 6 months after the primary injection, survival was 74.1% (20/27) with quantitative...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.12.028

    authors: Little SF,Ivins BE,Webster WM,Fellows PF,Pitt ML,Norris SL,Andrews GP

    更新日期:2006-03-24 00:00:00

  • A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.

    abstract::GPI-0100 is a semi-synthetic saponin with modifications designed to augment stability and diminish toxicity. Two batches of GPI-0100 (the second with higher purity) were tested with doses ranging between 100 and 5000 microg in groups of five treated prostate cancer patients who had no evidence of disease except for ri...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.01.072

    authors: Slovin SF,Ragupathi G,Fernandez C,Jefferson MP,Diani M,Wilton AS,Powell S,Spassova M,Reis C,Clausen H,Danishefsky S,Livingston P,Scher HI

    更新日期:2005-05-02 00:00:00

  • Probiotics and colostrum/milk differentially affect neonatal humoral immune responses to oral rotavirus vaccine.

    abstract::Breast milk (colostrum [col]/milk) components and gut commensals play important roles in neonatal immune maturation, establishment of gut homeostasis and immune responses to enteric pathogens and oral vaccines. We investigated the impact of colonization by probiotics, Lactobacillus rhamnosus GG (LGG) and Bifidobacteri...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.02.020

    authors: Chattha KS,Vlasova AN,Kandasamy S,Esseili MA,Siegismund C,Rajashekara G,Saif LJ

    更新日期:2013-04-08 00:00:00

  • Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008.

    abstract::The aim of this study was to characterize the adverse events of attenuated measles vaccine in mainland China. We carried out prospective follow-up of adverse events after mass measles immunization practices, categorizing them into two groups: allergic reactions and serious adverse events. The incidence of anaphylaxis ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.106

    authors: Shu M,Liu Q,Wang J,Ao R,Yang C,Fang G,Wan C,Guo W

    更新日期:2011-04-18 00:00:00

  • Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study.

    abstract:BACKGROUND:Native American populations experience a substantial burden of pneumococcal disease despite use of highly effective pneumococcal conjugate vaccines (PCVs). Protein-based pneumococcal vaccines may extend protection beyond the serotype-specific protection elicited by PCVs. METHODS:In this phase IIb, double-bl...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2019.09.076

    authors: Hammitt LL,Campbell JC,Borys D,Weatherholtz RC,Reid R,Goklish N,Moulton LH,Traskine M,Song Y,Swinnen K,Santosham M,O'Brien KL

    更新日期:2019-12-03 00:00:00

  • Early studies on DNA-based immunizations for measles virus.

    abstract::DNA-mediated immunizations have been used to raise neutralizing antibodies for measles virus. Single inoculations of plasmids expressing measles hemagglutinin or fusion glycoproteins raised neutralizing antibody in BALB/c mice. Plasmids expressing the hemagglutinin glycoprotein (both normal and secreted) raised neutra...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(96)00261-7

    authors: Yang K,Mustafa F,Valsamakis A,Santoro JC,Griffin DE,Robinson HL

    更新日期:1997-06-01 00:00:00

  • Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.

    abstract::Rotavirus (RV) is the primary etiologic agent of severe gastroenteritis in human infants. Although two attenuated RV-based vaccines have been licensed to be applied worldwide, they are not so effective in low-income countries, and the induced protection mechanisms have not been clearly established. Thus, it is importa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.03.080

    authors: Badillo-Godinez O,Gutierrez-Xicotencatl L,Plett-Torres T,Pedroza-Saavedra A,Gonzalez-Jaimes A,Chihu-Amparan L,Maldonado-Gama M,Espino-Solis G,Bonifaz LC,Esquivel-Guadarrama F

    更新日期:2015-08-20 00:00:00